The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Novel cell-based technologies for monitoring molecular interactions and/or cellular activity and high-throughput/high-content assay design
- Development of new technologies for cell culture, separations, and sorting, including flow cytometry and stem cells
- Development of new technologies for transgenic systems
- Development of new technologies and assays for genetics, genomics, and functional genomics
- Cryopreservation/vitrification of cells
Shared Interests and Overlaps
There are shared interests with Drug Discovery and Development (BCMB (10)). Applications using cells for drug discovery or pharmacological screenings may be assigned to BCMB (10). Applications developing new cell-based technologies and assays may be assigned to IMST (15).
There are shared interests with Biomaterials, Delivery, and Nanotechnology (BST (10)). Applications integrating cells into biomaterial constructs and/or studying the integration of biomaterials into cellular environments may be assigned to BST (10). Applications developing new cell-based technologies and assays may be assigned to IMST (15). Tissue engineering and microphysiological systems (e.g. organ-on-a-chip) applications are the domain of BST (10).
There are shared interests with Bioanalytical Chemistry, Biophysics, and Assay Development (IMST (10)). Applications developing assays or technologies that are not cell-based may be assigned to IMST (10). Applications developing assays with a cell component may be assigned to IMST (15).
There are shared interests with Instrumentation, Environmental, and Occupational Safety (IMST (12)). Applications developing technologies with a significant engineering component may be assigned to IMST (12), whereas applications having a dominant cell biology component may be assigned to IMST (15).
In the area of cryopreservation, there are shared interests with organ- and clinically-based small business panels. Applications developing cryopreservation strategies for organs and large tissues may be assigned to the relevant organ or clinically-based small business panel, whereas applications developing cryopreservation of cells may be assigned to IMST (15).